mTOR inhibitor
Everolimus
Brand names: Afinitor, Votubia, Certican
Adult dose
Dose: Oncology: 10mg OD. Transplant: 0.75–1.5mg BD adjusted to trough levels
Route: PO
Frequency: OD or BD
Clinical pearls
- Renal/breast cancer, NET, TSC, transplant
- Monitor trough levels in transplant
Contraindications
- Hypersensitivity
- Active severe infection
Side effects
- Stomatitis
- Non-infectious pneumonitis
- Hyperglycaemia
- Hyperlipidaemia
- Increased infection risk
- Wound-healing impairment
- Proteinuria
Interactions
- Strong CYP3A4/PgP modulators — major dose changes
- ACE inhibitors (angioedema risk in transplant)
- Live vaccines
Monitoring
- FBC
- Glucose
- Lipids
- LFTs
- U&E
- Trough levels (transplant)
Reference: BNF; NICE TA432/TA421; SmPC; https://bnf.nice.org.uk/drugs/everolimus/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Acute Myeloid Leukaemia Presentation · BSH; NICE — NG146
- Tumour Lysis Syndrome · Cairo-Bishop; BSH; NICE — Best Practice
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)